Antibody Drug Conjugates and Bystander Killing: is Antigen-dependent Internalisation Required?

Overview

Journal Br J Cancer

Specialty Oncology

Date 2017 Oct 25

PMID 29065110

Citations 184

Authors

Alexander H Staudacher

Michael P Brown

Affiliations

Soon will be listed here.

Abstract

Antibody drug conjugates (ADCs) employ the exquisite specificity of tumour-specific monoclonal antibodies (mAb) for the targeted delivery of highly potent cytotoxic drugs to the tumour site. The chemistry of the linker, which connects the drug to the mAb, determines how and when the drug is released from the mAb. This, as well as the chemistry of the drug, can dictate whether the drug can diffuse into surrounding cells, resulting in 'bystander killing'. Initially, any bystander killing mechanism of action of an ADC was understood to involve an essential sequence of steps beginning with surface antigen targeting, internalisation, intracellular linker cleavage, drug release, and diffusion of drug away from the targeted cell. However, recent studies indicate that, depending on the linker and drug combination, this mechanism may not be essential and ADCs can be cleaved extracellularly or via other mechanisms. In this minireview, we will examine the role of bystander killing by ADCs and explore the emerging evidence of how this can occur independently of internalisation.

Citing Articles

Development of Antibody-Drug Conjugates for Malignancies of the Uterine Corpus: A Review.

Yamanaka T, Nishikawa T, Yoshida H Cells. 2025; 14(5).

PMID: 40072062 PMC: 11898814. DOI: 10.3390/cells14050333.

Mirvetuximab Soravtansine Induces Potent Cytotoxicity and Bystander Effect in Cisplatin-Resistant Germ Cell Tumor Cells.

Kucerova L, Fekiacova A, Udvorkova N, Malcharkova P, Blahova V, Jochova S Cells. 2025; 14(4).

PMID: 39996761 PMC: 11853988. DOI: 10.3390/cells14040287.

Linking macrophage metabolism to function in the tumor microenvironment.

Jin R, Neufeld L, McGaha T Nat Cancer. 2025; 6(2):239-252.

PMID: 39962208 DOI: 10.1038/s43018-025-00909-2.

Antibody-Drug Conjugates Targeting CD30 in T-Cell Lymphomas: Clinical Progression and Mechanism.

Jiang Y, Dong S, Wang Y Cancers (Basel). 2025; 17(3).

PMID: 39941862 PMC: 11815818. DOI: 10.3390/cancers17030496.

Targeting uPAR with an antibody-drug conjugate suppresses tumor growth and reshapes the immune landscape in pancreatic cancer models.

Metrangolo V, Blomquist M, Dutta A, Gardsvoll H, Krigslund O, Norregaard K Sci Adv. 2025; 11(3):eadq0513.

PMID: 39823326 PMC: 11740940. DOI: 10.1126/sciadv.adq0513.

References

Fromm J, McEarchern J, Kennedy D, Thomas A, Shustov A, Gopal A . Clinical binding properties, internalization kinetics, and clinicopathologic activity of brentuximab vedotin: an antibody-drug conjugate for CD30-positive lymphoid neoplasms. Clin Lymphoma Myeloma Leuk. 2012; 12(4):280-3. DOI: 10.1016/j.clml.2012.01.012. View

Kung Sutherland M, Sanderson R, Gordon K, Andreyka J, Cerveny C, Yu C . Lysosomal trafficking and cysteine protease metabolism confer target-specific cytotoxicity by peptide-linked anti-CD30-auristatin conjugates. J Biol Chem. 2006; 281(15):10540-7. DOI: 10.1074/jbc.M510026200. View

Singh A, Sharma S, Shah D . Quantitative characterization of in vitro bystander effect of antibody-drug conjugates. J Pharmacokinet Pharmacodyn. 2016; 43(6):567-582. PMC: 5112145. DOI: 10.1007/s10928-016-9495-8. View

Masuda S, Miyagawa S, Sougawa N, Sawa Y . CD30-targeting immunoconjugates and bystander effects. Nat Rev Clin Oncol. 2015; 12(4). DOI: 10.1038/nrclinonc.2014.159-c1. View

Ansell S . Brentuximab vedotin. Blood. 2014; 124(22):3197-200. DOI: 10.1182/blood-2014-06-537514. View

Pro B, Advani R, Brice P, Bartlett N, Rosenblatt J, Illidge T . Brentuximab vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large-cell lymphoma: results of a phase II study. J Clin Oncol. 2012; 30(18):2190-6. DOI: 10.1200/JCO.2011.38.0402. View

Reddy V, Zhang Q, Weiss S . Pericellular mobilization of the tissue-destructive cysteine proteinases, cathepsins B, L, and S, by human monocyte-derived macrophages. Proc Natl Acad Sci U S A. 1995; 92(9):3849-53. PMC: 42059. DOI: 10.1073/pnas.92.9.3849. View

Bernardes G, Casi G, Trussel S, Hartmann I, Schwager K, Scheuermann J . A traceless vascular-targeting antibody-drug conjugate for cancer therapy. Angew Chem Int Ed Engl. 2011; 51(4):941-4. DOI: 10.1002/anie.201106527. View

Senter P, Sievers E . The discovery and development of brentuximab vedotin for use in relapsed Hodgkin lymphoma and systemic anaplastic large cell lymphoma. Nat Biotechnol. 2012; 30(7):631-7. DOI: 10.1038/nbt.2289. View

10.

Gerber H, Sapra P, Loganzo F, May C . Combining antibody-drug conjugates and immune-mediated cancer therapy: What to expect?. Biochem Pharmacol. 2015; 102:1-6. DOI: 10.1016/j.bcp.2015.12.008. View

11.

Dal Corso A, Cazzamalli S, Gebleux R, Mattarella M, Neri D . Protease-Cleavable Linkers Modulate the Anticancer Activity of Noninternalizing Antibody-Drug Conjugates. Bioconjug Chem. 2017; 28(7):1826-1833. PMC: 5521252. DOI: 10.1021/acs.bioconjchem.7b00304. View

12.

Bossard C, Dobay M, Parrens M, Lamant L, Missiaglia E, Haioun C . Immunohistochemistry as a valuable tool to assess CD30 expression in peripheral T-cell lymphomas: high correlation with mRNA levels. Blood. 2014; 124(19):2983-6. DOI: 10.1182/blood-2014-07-584953. View

13.

Kovtun Y, Audette C, Ye Y, Xie H, Ruberti M, Phinney S . Antibody-drug conjugates designed to eradicate tumors with homogeneous and heterogeneous expression of the target antigen. Cancer Res. 2006; 66(6):3214-21. DOI: 10.1158/0008-5472.CAN-05-3973. View

14.

Slack G, Steidl C, Sehn L, Gascoyne R . CD30 expression in de novo diffuse large B-cell lymphoma: a population-based study from British Columbia. Br J Haematol. 2014; 167(5):608-17. DOI: 10.1111/bjh.13085. View

15.

Oflazoglu E, Stone I, Brown L, Gordon K, van Rooijen N, Jonas M . Macrophages and Fc-receptor interactions contribute to the antitumour activities of the anti-CD40 antibody SGN-40. Br J Cancer. 2008; 100(1):113-7. PMC: 2634668. DOI: 10.1038/sj.bjc.6604812. View

16.

Sharkey R, Karacay H, Govindan S, Goldenberg D . Combination radioimmunotherapy and chemoimmunotherapy involving different or the same targets improves therapy of human pancreatic carcinoma xenograft models. Mol Cancer Ther. 2011; 10(6):1072-81. PMC: 5654622. DOI: 10.1158/1535-7163.MCT-11-0115. View

17.

Gebleux R, Stringhini M, Casanova R, Soltermann A, Neri D . Non-internalizing antibody-drug conjugates display potent anti-cancer activity upon proteolytic release of monomethyl auristatin E in the subendothelial extracellular matrix. Int J Cancer. 2016; 140(7):1670-1679. PMC: 5606289. DOI: 10.1002/ijc.30569. View

18.

Li F, Ulrich M, Jonas M, Stone I, Linares G, Zhang X . Tumor-Associated Macrophages Can Contribute to Antitumor Activity through FcγR-Mediated Processing of Antibody-Drug Conjugates. Mol Cancer Ther. 2017; 16(7):1347-1354. DOI: 10.1158/1535-7163.MCT-17-0019. View

19.

Miller M, Fishkin N, Li W, Whiteman K, Kovtun Y, Reid E . A New Class of Antibody-Drug Conjugates with Potent DNA Alkylating Activity. Mol Cancer Ther. 2016; 15(8):1870-8. DOI: 10.1158/1535-7163.MCT-16-0184. View

20.

Sloane B, Yan S, Podgorski I, Linebaugh B, Cher M, Mai J . Cathepsin B and tumor proteolysis: contribution of the tumor microenvironment. Semin Cancer Biol. 2005; 15(2):149-57. DOI: 10.1016/j.semcancer.2004.08.001. View